CA
RCUS icon

Clearstead Advisors’s Arcus Biosciences RCUS Stock Holding History

Clearstead Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155 Buy
+5
New +$124 ﹤0.01% 3267

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Clearstead Advisors's RCUS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 5 shares worth $155. The stake represents ﹤0.01% of the portfolio and ranks #3267 among its holdings.

229 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Clearstead Advisors held 5 shares of Arcus Biosciences worth $155 as of Q2 2026.
  • Arcus Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3267 holding.
  • 229 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.